Allogene Therapeutics

Market position

Allogene is a publicly traded, clinical-stage participant in the allogeneic cell therapy field, with programs spanning hematologic malignancies, solid tumors and autoimmune disease. Trade coverage groups it alongside Cellectis, Precision BioSciences, Imugene, Servier and Pfizer in the CD19-directed CAR-T landscape.

In contrast to autologous CAR T therapies made from each patient's own cells, Allogene's off-the-shelf products are made in advance from healthy-donor T cells, which the company positions as offering broader patient access without complex apheresis logistics, potential repeat dosing, scalable manufacturing with lower ancillary costs of care, on-demand treatment timing, and less product variability. ALPHA3 is described as the industry's first pivotal Phase 2 first-line consolidation trial of an investigational allogeneic CAR T in large B-cell lymphoma, and ALLO-316 as the first allogeneic CAR T product to show promise in solid tumors.

Technology

The AlloCAR T platform uses T cells from healthy donors that are isolated, engineered to express chimeric antigen receptors, and modified through gene editing — including elimination of the T-cell receptor in donor T cells intended to control graft-versus-host disease. The platform includes multiplex gene-engineering and gene-editing capabilities and Allogene's proprietary Dagger technology, designed to protect CAR T cells from host immune rejection and potentially reduce or eliminate the need for lymphodepleting chemotherapy. Manufacturing is performed at Cell Forge 1, a 136,000-square-foot modular facility in Newark, California, built for clinical and commercial manufacturing, analytical testing and distribution, with three production suites expandable to five, in-house quality assurance and control under cGMP, and LEEDv4 Interior Design and Construction Gold certification with 2,400 rooftop solar panels.

Go-to-market

The company advances candidates through company-sponsored clinical trials at investigator sites, publishes and presents data at medical congresses such as ASCO, AACR, SITC/IKCS and in peer-reviewed journals, and provides clinical trial resources, factsheets and brochures for healthcare providers. It does not currently operate expanded access protocols, directing patients to its trials. Commercial-scale supply is supported by its in-house Cell Forge 1 manufacturing facility.

Patients with large B-cell lymphoma including DLBCL, advanced or metastatic clear cell renal cell carcinoma, and autoimmune diseases such as lupus, lupus nephritis, myositis and systemic sclerosis, reached through treating physicians, clinical trial sites including community cancer centers, and — pending approval — payers and health systems.

Geography

Headquarters and principal executive offices are at 210 East Grand Avenue, South San Francisco, California, with the Cell Forge 1 manufacturing facility in Newark, California, in the eastern San Francisco Bay Area. Clinical activity extends internationally, including expansion of the pivotal Phase 2 ALPHA3 trial to South Korea and Australia in April 2026, and European rights to CD19-directed allogeneic CAR-T assets acquired from Servier in 2024.

History

Allogene Therapeutics, Inc. was incorporated in Delaware and filed a Form S-1 registration statement with the SEC on September 14, 2018 for an initial public offering, seeking to list on the Nasdaq Global Select Market under the ticker ALLO, with David Chang serving as President and Chief Executive Officer at the time. The company assumed Pfizer's strategic collaboration and licensing agreement with Cellectis covering allogeneic CAR T programs against defined targets. In May 2024 it acquired Servier's remaining European rights to CD19-directed allogeneic CAR-T assets, completing Servier's exit from cell therapy. Zachary Roberts serves as President and Chief Executive Officer, with co-founder Arie Belldegrun as Executive Chairman; a planned CEO succession was announced in May 2026. Longtime lead independent director David Bonderman served on the board from 2018 to 2025.

Risks & controversies

All of Allogene's products are investigational; the safety and efficacy of its allogeneic CAR T candidates have not been established and none are approved for commercial use by the FDA. Its 2018 IPO prospectus noted that investing in the common stock involves risks. Trade coverage characterized the 2024 purchase of Servier's remaining European CD19 allogeneic CAR-T rights as ending acrimony between the two companies.